Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | PDE1A | P54750 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20168403 | 0.91 | — | — | |
| SCHEMBL21411304 | 0.78 | HPGD (0.47) | ALDH1A1 | |
| SCHEMBL11392186 | 0.72 | NUDT1 (0.33) | ALDH1A1PDE5APDE1APDE1BPDE3B | |
| SCHEMBL22234302 | 0.72 | TDO2 (0.35) | ALDH1A1PDE5APDE1APDE1BPDE3B | |
| SCHEMBL11839119 | 0.72 | ALDH1A1 (0.33) | ALDH1A1PDE5APDE1APDE1BPDE3B | |
| SCHEMBL3683774 | 0.72 | PDE5A (0.36) | ALDH1A1PDE5APDE1APDE1BPDE3B | |
| SCHEMBL11836850 | 0.72 | CHRM4 (0.35) | ALDH1A1JAK2JAK1TYK2JAK3 | |
| SCHEMBL19815488 | 0.71 | ACMSD (0.42) | HCAR2 | |
| SCHEMBL20077896 | 0.69 | PDE5A (0.34) | PDE5APDE1APDE1BPDE3BPDE1C | |
| SCHEMBL22572956 | 0.69 | ALDH1A1 (0.34) | ALDH1A1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3953332-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2020210630-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-9023882-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-05-05 | — | — | US | disclosed |
| US-9023882-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-05-05 | — | — | US | disclosed |
| US-9023882-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-05-05 | — | — | US | disclosed |
| CN-101679244-B | 5-membered heterocyclic derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL | 2014-01-01 | — | — | CN | disclosed |
| US-20120289506-A1 | 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-20120289506-A1 | 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-20120289506-A1 | 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-8227500-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-8227500-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-8227500-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-20100227864-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100227864-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100227864-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-09 | — | — | US | disclosed |
| CN-101679244-A | 5-membered heterocyclic derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL | 2010-03-24 | — | — | CN | disclosed |
| EP-2133331-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Kissei Pharmaceutical Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227864-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, CBR1 | ALDH1A1 700/4885PDE5A 736/4885PDE1A 2998/4885 |
| US-20120289506-A1 | 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | XDH, DAO, DDO | ALDH1A1 1225/4885PDE5A 665/4885PDE1A 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.